Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Study of ABBV-932 Receptor Occupancy
NCT06300580Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABBV-932 in bipolar disorder (BD) and generalized anxiety disorder (GAD), sponsored by AbbVie Inc. Primary endpoints: Change in Dopamine Receptor Occupancy in Brain Measured by Positron Emission Tomography (PET) up to 14 days and Number of Participants with Adverse Events (AEs) up to 74 days. Started Aug 2024; status: completed.
02
Drugs
ABBV-932
03
Conditions
bipolar disorder (BD)generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT06300580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06300580.